Veradermics Q2 Loss Widens to $23.5M, Cash Runway Extended to 2030
MANE has more than doubled off its 52-week low of $32.
Summary
Veradermics reported a Q2 net loss of $23.5 million, wider than the prior year, driven by higher R&D and G&A expenses tied to VDPHL01 clinical development and commercial readiness. The company ended the quarter with $819.9 million in cash, which it expects to fund operations into 2030, including a potential VDPHL01 launch. This follows the July Phase 2 success in female pattern hair loss and an S-1 filing last week to register 16.8 million shares for resale. Topline Phase 3 data in men is expected in the second half of 2026, a key catalyst for the stock.
At the time of this announcement, MANE was trading at $110.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $4.6B. The 52-week trading range was $32.00 to $131.24. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.